Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer, including those with estr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardia, Aditya, Kaklamani, Virginia, Wilks, Sharon, Weise, Amy, Richards, Donald, Harb, Wael, Osborne, Cynthia, Wesolowski, Robert, Karuturi, Meghan, Conkling, Paul, Bagley, Rebecca G., Wang, Yamei, Conlan, Maureen G., Kabos, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078341/
https://www.ncbi.nlm.nih.gov/pubmed/33513026
http://dx.doi.org/10.1200/JCO.20.02272

Ejemplares similares

Ejemplares similares